POLICY · MODELS · #3429
AlphaGenome 2: conditional DNA sequence model predicts variant effects in specific cell types
AlphaGenome 2 is a next-generation DNA-sequence model that predicts how sequence variants affect molecular readouts (gene expression, chromatin accessibility, histone marks, DNA methylation) in specific human cell types and states. Trained on over 107 million individual cell profiles across 68 tissues, it uses a conditional architecture that takes a biological condition plus a DNA sequence, improves detection of cell-type–specific regulatory variants versus the prior model, supports cross-modality imputation, and is available for non-commercial research via the AlphaGenome API (commercial preview private).
KEY POINTS
- AlphaGenome 2 is a next-generation DNA-sequence model that predicts how sequence variants affect molecular readouts (gene expression, chromatin accessibility, histone marks, DNA methylation) in specific human cell types and states.
- Trained on over 107 million individual cell profiles across 68 tissues, it uses a conditional architecture that takes a biological condition plus a DNA sequence, improves detection of cell-type–specific regulatory variants versus the prior model, supports cross-modality imputation, and is available for non-commercial research via the AlphaGenome API (commercial preview private).
- AlphaGenome 2 matters because its cell‑conditional predictions and improved sensitivity unlock detection and interpretation of disease-relevant variants that bulk-tissue models miss, accelerating genetic and cell‑level discoveries.
WHY IT MATTERS
AlphaGenome 2 matters because its cell‑conditional predictions and improved sensitivity unlock detection and interpretation of disease-relevant variants that bulk-tissue models miss, accelerating genetic and cell‑level discoveries.